Piramal’s wholly-owned Critical Care subsidiary in the UK has signed an agreement to acquire five anesthesia and pain management injectable products from Janssen Pharmaceutica for $155m, and up to an additional $20m.

As part of the agreement, five injectable versions of Janssen brands, Sublimaze (fentanyl citrate), Sufenta (sufentanil citrate), Rapifen (alfentanil hydrochloride), Dipidolor (piritramide), and Hypnomidate (etomidate) will be acquired.

The acquisition of the brand names and all related IP as associated with the products will enable Piramal to boost growth in the healthcare businesses, organically as well as inorganically.

"Four of the acquired products are controlled substances which have higher barriers to entry."

The company will also have the ability to make both the active pharmaceutical ingredients (API) and the finished dosage forms of the products.

At present, the products are marketed in more than 50 countries.

Piramal chairman Ajay Piramal said: “The healthcare segment has grown at 17% compound annual growth rate (CAGR) over the last five years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This acquisition is an important step in enabling Piramal Critical Care to start to address the global generic injectable hospital drug market which is greater than $20bn in size.”

Janssen said it will continue to supply finished dosage forms for up to three years and API for up to five years.

Until the marketing authorisations are transferred to Piramal, Janssen will also continue to sell the products on behalf of Piramal.

Piramal Critical Care CEO Peter DeYoung said: “Four of the acquired products are controlled substances which have higher barriers to entry.

“Once the business is fully transitioned to us, our customers and business partners will benefit from our broader product basket, and in turn we can grow the value of the acquired product portfolio through our team’s focused sales and marketing efforts.”